Recent

% | $
Quotes you view appear here for quick access.

Marvell Technology Group Ltd. Message Board

repo_man_one 40 posts  |  Last Activity: Apr 29, 2015 9:37 PM Member since: Sep 6, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Quotient Clinical Osteoarthritis Trial

    by repo_man_one Apr 29, 2015 12:10 PM
    repo_man_one repo_man_one Apr 29, 2015 9:37 PM Flag

    How does that relate to this Quotient Clinical trail?
    Have you looked at the Quotient Clinical recruitment web site for this trial?

  • I see Quotient Clinical is recruiting for a drug study, starting in mid May, for Osteoarthritis pain.
    Anyone know if this is associated with RCPI?

    Study reference: QCL-117375 part A

    Study description:
    The purpose of the study is to investigate the study drug which is being developed as a treatment for Osteoarthritis pain. This study has been designed to look at the safety of the drug, how the body tolerates the drug and how the drug is taken up in your body when administered at different dose levels.

  • Reply to

    Aduro BioTech

    by repo_man_one Apr 15, 2015 11:35 AM
    repo_man_one repo_man_one Apr 15, 2015 12:57 PM Flag

    "Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discount. Aduro’s common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “ADRO” on April 15, 2015."

    Current Price = $34.77

  • repo_man_one by repo_man_one Apr 15, 2015 11:35 AM Flag

    Anybody out there watching the IPO of this company?
    If not check it out.
    This from a recent press release.

    "We announced the promising initial results from the first Phase 2 trial of this combination therapy at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium. Based on these data we have designed and initiated ECLIPSE, a Phase 2b trial that will enroll approximately 300 adults..."

    I am looking forward to when RCPI can start Phase 2 testing

  • Reply to

    Today's 8K

    by jk224_pmc Apr 8, 2015 6:43 PM
    repo_man_one repo_man_one Apr 8, 2015 8:09 PM Flag

    Looks to me like there are (or were) multiple people on the board who thought they held the title of CEO.
    A Classic CEO food fight.

    As far as I am concerned, at the end of the day the clinical trial status is what's most important.

  • repo_man_one by repo_man_one Apr 8, 2015 7:54 PM Flag

    On April 1, 2015, some of the Company’s Board of Directors learn that an IND clinical hold response had been PREMATURELY submitted to the FDA, WITHOUT THE KNOWLEDGE of key members of Company management, sometime back in FEBRUARY !!!!

    Then the FDA issues some type of response to that filing on March 20, 2015, but Key Management and (some) Board members don’t learn about any of this until April 1st !!!!

    Then one day later, on April 2, one of the board members resigns. While another board member has been placed on paid administrative leave pending an investigation !!!!

    MEANWHILE

    While all of this is going on the Company completed a clinical trial in New Zealand.

    The Company’s multi-part UK clinical trial is continuing, and the Company has completed recruitment (in Part 1) and three formulations have been tested with no safety concerns, and pharmacokinetic analysis is ongoing.

  • Reply to

    Sanofi takeover of RCPI close: Report

    by sheezyrncneezy Mar 27, 2015 8:38 PM
    repo_man_one repo_man_one Mar 27, 2015 9:03 PM Flag

    That would first need to be approved by shareholders, wouldn't it?

  • repo_man_one by repo_man_one Mar 15, 2015 3:01 PM Flag

    “The nutritional supplement variant of Anatabine Citrate has received "MedSafe" approval from the New Zealand Medicines and Medical Devices Safety Authority , which has allowed the Company to conduct a clinical study in New Zealand. …”

    Does this mean the company is working to get approval to sell a nutraceutical version in places outside the US?

  • "Our company also received “MedSafe” approval from the New Zealand Medicines and Medical Devices Safety Authority allowing us to conduct a clinical study in New Zealand. In December 2014, the company received a New Zealand Ministry of Health Ethics Committee approval to conduct a single-site, open-label human study, entitled “Determination of the Blood Pharmacodynamic Effects following a Single Dose of Oral Anatabine Citrate in Normal, Healthy Volunteers”. The primary outcome measure was the pharmacodynamic assessment of inflammatory markers including the expression and/or production of pro-inflammatory mediators from peripheral blood cells. This study will offer further insights into anatabine citrate’s anti-inflammatory mechanism of action in human blood. We have completed the clinical part of the study and should have results with analysis and commentary in March 2015."

    Results with analysis and commentary in March 2015 ????

  • Reply to

    Enduring Memory

    by repo_man_one Mar 2, 2015 5:26 AM
    repo_man_one repo_man_one Mar 2, 2015 12:01 PM Flag

    JW is long gone Bozo

  • repo_man_one by repo_man_one Mar 2, 2015 5:26 AM Flag

    Checkout the new article at SRQ Magazine.
    Ties in nicely with recent statements by Fiona Crawford

  • Reply to

    Interim Results?

    by pharma_treasure Feb 24, 2015 4:25 PM
    repo_man_one repo_man_one Feb 24, 2015 6:27 PM Flag

    Makes sense, looks like four of the six trials will be completed before the shareholders meeting.

  • Reply to

    Big Day on Monday

    by twicesilent23 Feb 22, 2015 11:38 AM
    repo_man_one repo_man_one Feb 23, 2015 6:46 PM Flag

    You were right, twicesilent23 looks like an idiot

  • Reply to

    We have a LOT of interesting compounds

    by repo_man_one Feb 20, 2015 12:26 PM
    repo_man_one repo_man_one Feb 20, 2015 4:52 PM Flag

    At least I don't sit around all day writing stupid poems for particular purpose.

  • Reply to

    Q and A aout Rock Creek

    by abi_lgm_2007 Feb 19, 2015 1:36 PM
    repo_man_one repo_man_one Feb 20, 2015 4:48 PM Flag

    You sound bitter,
    Given that extensive rant, surely you have sold?

    If not, are you feeling uneasy about your decision, or are you just trying to convince yourself you made the right decision and want others to confirm?

  • Reply to

    We have a LOT of interesting compounds

    by repo_man_one Feb 20, 2015 12:26 PM
    repo_man_one repo_man_one Feb 20, 2015 4:40 PM Flag

    Why do you think I have the answers to all those questions?
    You have previously said you were at the meeting last March.
    I suggest you ask management those questions.

    If you think the company will be broke at the end of Feb, then what you should do should be clear, shouldn't it?

  • Reply to

    We have a LOT of interesting compounds

    by repo_man_one Feb 20, 2015 12:26 PM
    repo_man_one repo_man_one Feb 20, 2015 4:31 PM Flag

    It's goes much higher than that.
    Google - Obama Boosts Concussion And TBI Injury Awareness, Calls For An End To 'Suck It Up'

  • Reply to

    We have a LOT of interesting compounds

    by repo_man_one Feb 20, 2015 12:26 PM
    repo_man_one repo_man_one Feb 20, 2015 1:57 PM Flag

    Speaking of valuation, given all of the shorting and illegal naked shorting, it would not surprise me to see Archer Pharmaceuticals make an offer to buy RCPI.

    As a shareholder, I would have no problem voting my shares to approve a merger with Archer.

  • Reply to

    We have a LOT of interesting compounds

    by repo_man_one Feb 20, 2015 12:26 PM
    repo_man_one repo_man_one Feb 20, 2015 1:25 PM Flag

    A Clinical trial, very interesting.
    I had not seen.
    Thanks

  • WARNING – the shorts won’t like this but …
    did anyone listen to the Fiona Crawford radio broadcast?

    If not, it was an extremely interesting discussion about Alzheimer’s and the linkage to inflamation/TBI.

    A link to this radio broadcast can be found over at the Hub, or you can also google - Crawford WSRQ Radio and look for the Salt & Light Radio Feb 7th 2015 broadcast.

    At the very end of that radio broadcast, Fiona Crawford says -

    “We have a LOT of interesting compounds at the institute which look MORE POTENT than the drug we have in Europe....“

    More Potent?

    Given prior presentations Fiona Crawford has made on TBI, anatabine, and inflamation, is there any doubt one of the other “interesting compounds” is anatabloc, or perhaps a time release version of anatabloc?

MRVL
13.90-0.27(-1.91%)May 5 4:00 PMEDT